nach oben

Erschienen in:

01.07.2013 | Original article

Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer

verfasst von: Dr. P. Georg, MD, A. Boni, MD, A. Ghabuous, MD, G. Goldner, MD, M.P. Schmid, MD, D. Georg, PhD, R. Pötter, MD, W. Dörr, DVM, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

To analyze the time course of late rectal- and urinary bladder complications after brachytherapy for cervical cancer and to compare the incidence- and prevalence rates thereof.

Patients and methods

A total of 225 patients were treated with external-beam radiotherapy (EBRT) and magnetic resonance imaging (MRI)-guided brachytherapy with or without chemotherapy. Late side effects were assessed prospectively using the Late Effects in Normal Tissue—Subjective, Objective, Management and Analytic (LENT/SOMA) scale. The parameters analyzed were time to onset, duration, actuarial incidence- (occurrence of new side effects during a defined time period) and prevalence rates (side effects existing at a defined time point).

Results

Median follow-up was 44 months. Side effects (grade 1–4) in rectum and bladder were present in 31 and 49 patients, 14 and 27 months (mean time to onset) after treatment, respectively. All rectal and 76 % of bladder side effects occurred within 3 years after radiotherapy. Mean duration of rectal events was 19 months; 81 % resolved within 3 years of their initial diagnosis. Mean duration of bladder side effects was 20 months; 61 % resolved within 3 years. The 3- and 5-year actuarial complication rates were 16 and 19 % in rectum and 18 and 28 % in bladder, respectively. The corresponding prevalence rates were 9 and 2 % (rectum) and 18 and 21 % (bladder), respectively.

Conclusion

Late side effects after cervical cancer radiotherapy are partially reversible, but their time course is organ-dependent. The combined presentation of incidence- and prevalence rates provides the most comprehensive information.

Barker CL, Routledge JA, Farnell DJJ et al (2009) The impact of radiotherapy late effects on quality of life in gynaecological cancer patients. Br J Cancer 100:1558–1565PubMedCrossRef

Barraclough LH, Routledge JA, Farnell DJ et al (2012) Prospective analysis of patient-reported late toxicity following pelvic radiotherapy for gynaecological cancer. Radiother Oncol 103:327–332PubMedCrossRef

Chargari C, Magne N, Dumas I et al (2009) Physics contributions and clinical outcome with 3D-MRI-based pulse-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 74:133–139PubMedCrossRef

Davidson SE, Burns MP, Routledge JA et al (2003) Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and Franco-Italian glossary. Radiother Oncol 69:195–200PubMedCrossRef

Dimopoulos JC, Lang S, Kirisits C et al (2009) Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 75:56–63PubMedCrossRef

Dimopoulos JC, Pötter R, Lang S et al (2009) Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 93:311–315PubMedCrossRef

Eifel PJ, Levenback C, Wharton JT et al (1995) Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 32:1289–1300PubMedCrossRef

Georg P, Kirisits C, Goldner G et al (2009) Correlation of dose-volume-parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI based brachytherapy. Radiother Oncol 91:173–180PubMedCrossRef

Georg P, Lang S, Dimopoulos JC et al (2011) Dose-volume histogram parameters and late side effects in magnetic resonance image-guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 79:356–362PubMedCrossRef

10.

Georg P, Pötter R, Georg D et al (2012) Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 82:653–657PubMedCrossRef

11.

Gruen A, Musik T, Köhler J et al (2011) Adjuvant chemoradiation after laparoscopically assisted radical vaginal hysterectomy (LARVH) in patients with cervical cancer. Strahlenther Onkol 187:344–349PubMedCrossRef

12.

Haie-Meder C, Kramar A, Lambin P et al (1994) Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys 29:953–960PubMedCrossRef

13.

Haie-Meder C, Pötter R, Limbergen E van et al (2005) Recommendations from the Gynaecological (GYN) GEC-ESTRO working group: concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74:235–245PubMedCrossRef

14.

Haie-Meder C, Chargari C, Rey A et al (2009) DVH parameters and outcome for patients with early-stage cervical cancer treated with preoperative MRI-based low dose rate brachytherapy followed by surgery. Radiother Oncol 93:316–321PubMedCrossRef

15.

Haie-Meder C, Chargari C, Rey A et al (2010) MRI-based low dose-rate brachytherapy experience in locally advanced cervical cancer patients initially treated by concomitant chemoradiotherapy. Radiother Oncol 96:161–165PubMedCrossRef

16.

Heinzelmann F, Henke G, Grafenstein M von et al (2012) Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer. Strahlenther Onkol 188:568–575PubMedCrossRef

17.

Kirchheiner K, Nout R, Lindegaard J et al (2012) Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients. Strahlenther Onkol 188:933–939PubMedCrossRef

18.

Kirchheiner K, Fidarova E, Nout RA et al (2012) Radiation-induced morphological changes in the vagina. Strahlenther Onkol 188:1010–1019CrossRef

19.

Kirisits C, Pötter R, Lang S et al (2005) Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 62:901–911PubMedCrossRef

20.

Lang S, Nulens A, Briot E et al (2006) Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations. Radiother Oncol 78:185–193PubMedCrossRef

21.

Lang S, Kirisits C, Dimopoulos J et al (2007) Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints. Int J Radiat Oncol Biol Phys 69:619–627PubMedCrossRef

22.

(o A) (1995) LENT SOMA tables. Int J Radiat Oncol Biol Phys 31:1048–1092

23.

Levitchi M, Charra-Brunaud C, Quetin P et al (2012) Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy. Radiother Oncol (in press)

24.

Pavy JJ, Denekamp J, Letschert J et al (1995) EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol 35:11–15PubMedCrossRef

25.

Pötter R, Haie-Meder C, Limbergen E van et al (2006) Recommendations from gynaecological (GYN) GEC-ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78:67–77PubMedCrossRef

26.

Pötter R, Dimopoulos J, Georg P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83:148–155PubMedCrossRef

27.

Pötter R, Georg P, Dimopoulos JA et al (2011) Clinical outcome of image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123PubMedCrossRef

28.

Routledge JA, Burns MP, Swindell R et al (2003) Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. Int J Radiat Oncol Biol Phys 56:502–510PubMedCrossRef

29.

Rubin P, Constine LS, Fajardo L et al (1995) Overview: late effects of normal tissue (LENT) scoring system. Int J Radiat Oncol Biol Phys 31:1041–1042PubMedCrossRef

30.

Schmid MP, Pötter R, Bombosch V et al (2012) Late gastrointestinal and urogenital side-effects after radiotherapy-Incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer. Radiother Oncol 104:114–148PubMedCrossRef

31.

Schmid MP, Mansmann B, Federico M et al (2013) Residual tumour volumes and grey zones after external beam radiotherapy (± chemotherapy) in cervix cancer patients: a low-field MRI study. Strahlenther Onkol 189:238-245PubMedCrossRef

32.

Schmid MP, Pötter R, Brader P et al (2013) Feasibility of transrectal ultrasonography in the assessment of locally advanced cervical cancer in the course of primary radiochemotherapy. Strahlenther Onkol 189:123-128PubMedCrossRef

33.

Stock M, Dörr W, Stromberger C et al (2010) Investigations on parotid gland recovery after IMRT in head and neck tumor patients. Strahlenther Onkol 186:665–671PubMedCrossRef

Titel: Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer
verfasst von: Dr. P. Georg, MD
A. Boni, MD
A. Ghabuous, MD
G. Goldner, MD
M.P. Schmid, MD
D. Georg, PhD
R. Pötter, MD
W. Dörr, DVM, PhD
Publikationsdatum: 01.07.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0365-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Prädiktoren für ein lokoregionäres Rezidiv nach neoadjuvanter Chemotherapie beim Mammakarzinom

Kardiale Risiken der adjuvanten Radiotherapie beim Mammakarzinom

Validation and practical implementation of a multidisciplinary cancer distress screening questionnaire

Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma

Acute mucosal reactions in patients with head and neck cancer

Mitteilungen der Fachgesellschaften

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie